The pharmaceutical and biotechnology industries are doing everything in their power to prepare for all scenarios and need the support of the European Union to ensure that we can fulfil our promise to the patients who we serve.
The associations representing the European and British life science industry have today responded to the European Council approving terms of the transition period agreed between the UK Government and EU.
The European Health Community has warned that time is running out to secure patients’ interests in Brexit negotiations. With Phase 2 of the negotiations looming, health groups across Europe have drawn up a list of crucial unanswered questions that must be answered by the EU and UK negotiators to ‘put patients first’ in the negotiations.
The life science industry is highly integrated across Europe and regulated under EU law through a sophisticated system of legal and regulatory arrangements involving EU Institutions, MS and national competent authorities.